Risk factors for side effects during first infusion of rituximab—definition of a low risk group-Reference-Cited by-同舟云学术

Risk factors for side effects during first infusion of rituximab—definition of a low risk group

Published:2000-08 Issue:3 Volume:17 Page:218-221
ISSN:1357-0560
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Hagberg H,Holmbom E

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/BF02780531.pdf

Reference6 articles.

1. McLaughlin Pet al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.J Clin Oncol 1998;16: 2825–2833.

2. Byrd JCet al. Rituximab therapy in hematological malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor celarence.J Clin Oncol 1999;17: 791–795.

3. Winkler Uet al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8).Blood 1999;94: 2217–2224.

4. Czuczman MSet al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.J Clin Oncol 1999;17: 268–276.

5. Link BKet al. Phase II pilot study of the safety and efficacy of rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate-and high grade non-Hodgkins lymphoma.Proc Am Soc Clin Oncol 1998;17: 3a. Abstract 7.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patients with infusion-related reactions on fixed-dose rituximab treatment have higher body surface area than those without infusion-related reactions in adults with frequently relapsing minimal change nephrotic syndrome: a retrospective study;Journal of Pharmaceutical Health Care and Sciences;2024-02-22

2. Analysis of Risk Factors for Infusion-Related Reactions Following Rituximab Administration in Patients with Desensitization before Renal Transplantation;Biological and Pharmaceutical Bulletin;2023-09-01

3. Expanded utilization of rituximab in paediatric cardiac transplant patients;Journal of Clinical Pharmacy and Therapeutics;2021-01-04

4. Sensitization in Heart Transplantation: Emerging Knowledge: A Scientific Statement From the American Heart Association;Circulation;2019-03-19

5. Risk factors for developing infusion reaction after rituximab administration in patients with B-cell non-Hodgkin's lymphoma;PHARMAZIE;2015